Gestalt, I always enjoy your posts, but I think re
Post# of 148282
I would suggest that we may be at a point where it is not wise to assume the competence of CYDY management with respect to all matters.
On any given matter, they may or may not be competent, but I do not believe it's safe to assume competence across the board anymore. It is time for CYDY management to demonstrate competence.
Earlier this year I would have said to myself "do you really believe CYDY will work on the BLA for years, with a rolling filing permitted, and not submit the BLA in the correct format with complete information?"
More recently, I also would have said "surely they would not tell us to expect interim analysis on the first 50 PATIENTS in the S/C trial and then ACTUALLY do an interim analysis at 195?"
Or "surely they would not tell us they requested EUA but not actually formally request/apply?"
All that is to say, I don't assume their competence with respect to a NASDAQ uplist anymore. If it happens, fantastic. But I am not holding my breath...
Quote:
Do you really think they would go through the effort to apply for uplisting if they did not meet the requirements? That would be a colossal screw up. It costs around $150k/yr to be on the nasdaq, they likely know every detail of the process and what the requirements are.